EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Accretion Pharmaceuticals's Enterprise Value is ₹1,813.2 Mil.
Accretion Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-231.5 Mil. Therefore, Accretion Pharmaceuticals's EV-to-FCF for today is -7.83.
The historical rank and industry rank for Accretion Pharmaceuticals's EV-to-FCF or its related term are showing as below:
NSE:ACCPL'
s EV-to-FCF Range Over the Past 10 Years
Min: -7.83 Med: 17.12 Max: 27.14
Current: -7.83
During the past 5 years, the highest EV-to-FCF of Accretion Pharmaceuticals was 27.14. The lowest was -7.83. And the median was 17.12.
NSE:ACCPL's EV-to-FCF is ranked worse than 100% of 563
companies
in the Drug Manufacturers industry
Industry Median: 20.85
vs NSE:ACCPL: -7.83
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Accretion Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Accretion Pharmaceuticals's share price for today is ₹159.00.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Accretion Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹9.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Accretion Pharmaceuticals EV-to-FCF Related Terms
Accretion Pharmaceuticals EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's EV-to-FCF falls into.
Accretion Pharmaceuticals's current Enterprise Value is ₹1,813.2 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Accretion Pharmaceuticals's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-231.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals (NSE:ACCPL) has a EV-to-FCF of -7.83 as of Jul. 06, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Accretion Pharmaceuticals and its competitors. According to the industry distribution chart, Accretion Pharmaceuticals ranks #999999 out of 563 companies in the Drug Manufacturers industry.
Is Accretion Pharmaceuticals' EV-to-FCF too high?
Accretion Pharmaceuticals' current EV-to-FCF is -7.83. Based on the distribution chart, Accretion Pharmaceuticals ranks #999999 out of 563 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Accretion Pharmaceuticals has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' EV-to-FCF compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #999999 out of 563 companies for EV-to-FCF. This places Accretion Pharmaceuticals in the lower half of its industry. The industry median EV-to-FCF is 20.85. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.85, based on 563 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current EV-to-FCF is -7.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current EV-to-FCF of -7.83. The current EV-to-FCF is -7.83. Accretion Pharmaceuticals' overall GF Score™ is 30/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current EV-to-FCF is -7.83 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
30GF Score
Get the complete analysis for NSE:ACCPL
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 